Page 6 - பொருள் நிபுணர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பொருள் நிபுணர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பொருள் நிபுணர் Today - Breaking & Trending Today

Bharat Biotech Oxford Covaxin Covishield Serum Institute DCGI final approval coronavirus vaccine emergency use

URL copied
Covishield, Covaxin get govt s nod
Drug Controller General of India (DCGI) on Sunday approved Serum Institute of India s Covishield vaccine and Bharat Biotech s Covaxin for emergency use against coronavirus. The development, eleven months after the first case of deadly coronavirus was detected in India, has paved the way for their roll-out and administration to millions. The vaccine will be first offered to one crore healthcare workers, along with two crore frontline and essential workers and 27 crores elderly, mostly above the age of 50 years with co-morbidities.
The expert panel has recommended granting permission for restricted emergency use of Covaxin in public interest as an abundant precaution, in clinical trial mode, especially in the context of infection by mutant strains. ....

United Kingdom , Oxford Astrazeneca Covishield , Astrazeneca Oxford University , Serum Institute Of India Covishield , National Institute Of Virology , Indian Council Of Medical Research , Cadila Healthcare Ltd , Expert Committee , Serum Institute Of India , Image Source , Controller General , Serum Institute , Bharat Biotech , Subject Expert Committee , Central Drugs Standard Control Organisation , Restricted Emergency Approval , Cadila Healthcare , Recombinant Chimpanzee Adenovirus , Whole Virion Inactivated Corona Virus Vaccine , Novel Corona , Subject Expert , Oxford Astrazeneca , Indian Council , Medical Research , Bharat Biotech Pfizer , National Institute ,

DCGI issues restricted emergency approval of COVID-19 vaccines

SII and Bharat Biotech vaccines have to be administered in two doses ....

Narendra Modi , Astrazeneca Oxford University , Cadila Healthcare Ltd , Serum Institute Of India , Expert Committee , Subject Expert Committee , Central Drugs Standard Control Organisation , Restricted Emergency Approval , Serum Institute , Bharat Biotech , Cadila Healthcare , Recombinant Chimpanzee Adenovirus , Whole Virion Inactivated Corona Virus Vaccine , Novel Corona , Subject Expert , Prime Minister , Serum Inst , Covid 19 , நரேந்திர மோடி , காடிலா சுகாதாரம் லிமிடெட் , சீரம் நிறுவனம் ஆஃப் இந்தியா , நிபுணர் குழு , பொருள் நிபுணர் குழு , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , தடைசெய்யப்பட்டுள்ளது அவசரம் ஒப்புதல் , சீரம் நிறுவனம் ,

Dalal Street Week Ahead: Here Are 10 Key Factors That Will Keep The Traders Busy

Dalal Street Week Ahead: Here are 10 key factors that will keep the traders busy
Rusmik Oza of Kotak Securities expects the Nifty50 to go somewhere mid way of the 14,000 to 15,000 range in January.
Sunil Shankar Matkar
January 03, 2021 / 08:21 AM IST
The positive global cues helped the market gain momentum after consolidation seen in the previous week, and close above psychological 14,000 mark on the Nifty50 for the week ended January 1, 2021. The signing of second stimulus package by the United States, the approval for Brexit deal by the European Union & UK, and the development related to rollout of COVID-19 vaccine lifted sentiment.
The BSE Sensex jumped 895.44 points, or 1.91 percent, to 47,868.98 and the Nifty50 rose 269.25 points, or 1.96 percent, to 14,018.50, while the broader markets outpaced benchmarks with the Nifty Midcap index climbing 3 percent and Smallcap gaining 3.88 percent. ....

United States , United Kingdom , Harsh Vardhan , Nirali Shah , Vinod Paul , Anand Rathi , Nilesh Jain , Union Territories , Johns Hopkins University , European Union United Kingdom , Capital Services , Union Budget , Tata Consultancy Services , Serum Institute Of India , Head Of Fundamental Research At Kotak Securities , Radix Industries , Union Health , Markit Services , Senior Research Analyst At Samco Securities , India Inc , Central Drugs Standard Control Organization , Expert Committee , European Union , Nifty Midcap , Senior Research Analyst , Samco Securities ,

COVID-19 vaccines of SII, Bharat Biotech approved for restricted use in emergency situation

COVID-19 vaccines of SII, Bharat Biotech approved for restricted use in emergency situation
ANI |
Updated: Jan 03, 2021 11:36 IST
New Delhi [India], January 3 (ANI): COVID-19 vaccines of Serum Institue of India and Bharat Biotech have been granted permission for restricted use in emergency situation, said Drugs Controller General of India (DCGI) on Sunday.
After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to M/s Cadila Healthcare for conduct of the Phase III clinical trial, said VG Somani, DCGI, during a media briefing today. ....

New Delhi , National Institute Of Virology , Standard Drug Organisation , Cadila Healthcare Ltd , Expert Committee , Serum Institue , Bharat Biotech , Drugs Controller General , Cadila Healthcare , National Institute , Subject Expert Committee , Novel Corona , Subject Expert , Dcgi Media Briefing , Covid 19 , Corona Virus , புதியது டெல்ஹி , தேசிய நிறுவனம் ஆஃப் வைராலஜி , தரநிலை மருந்து ஆர்கநைஸேஶந் , காடிலா சுகாதாரம் லிமிடெட் , நிபுணர் குழு , சீரம் நிறுவனம் , பாரத் பயோடெக் , மருந்துகள் கட்டுப்படுத்தி ஜநரல் , காடிலா சுகாதாரம் , தேசிய நிறுவனம் ,

Coronavirus Vaccine: Restricted emergency use approval for Serum's Covishield and Bharat Biotech's Covaxin

Coronavirus Vaccine: Restricted emergency use approval for Serum s Covishield and Bharat Biotech s Covaxin
Coronavirus Vaccine: Restricted emergency use approval for Serum s Covishield and Bharat Biotech s Covaxin
Mirror Online / Updated: Jan 3, 2021, 12:07 IST
Photo by Mahendra Kolhe/MMCL
In a two minute statement read out to the media on Sunday morning, India s drug regulatory body announced it has granted emergency restricted use approval to two Covid-19 vaccines. These two are Serum Institute s
Covishield and
Bharat Biotech s
Covaxin. The Drug Controller also announced that it has granted permission to Cadila to conduct phase 3 clinical trials. No questions were taken and the briefing was wrapped up after the brief announcement. ....

Adar Poonawalla , Serum Institute , Cadila Healthcare Ltd , Serum Institute Of India , Expert Committee , Drug Controller , Bharat Biotech , Cadila Healthcare , Restricted Emergency Approval , Whole Virion Inactivated Corona Virus Vaccine , Healthcare Ltd , Novel Corona , Subject Expert , Corona Virus , Covid Vaccine , India Vaccination , அடார் பூனாவல்ல , சீரம் நிறுவனம் , காடிலா சுகாதாரம் லிமிடெட் , சீரம் நிறுவனம் ஆஃப் இந்தியா , நிபுணர் குழு , மருந்து கட்டுப்படுத்தி , பாரத் பயோடெக் , காடிலா சுகாதாரம் , தடைசெய்யப்பட்டுள்ளது அவசரம் ஒப்புதல் , சுகாதாரம் லிமிடெட் ,